Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower
pace than non–small-cell lung cancer. In fact, the standard treatment regimen for limited …

Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a
particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage …

PURPOSE Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard
for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily …

Rationale: Cisplatin nephrotoxicity is an important cause of acute kidney injury (AKI), limiting
cisplatin application in cancer therapy. Growing evidence has suggested that genome …

Despite the progress in outcomes seen with immunotherapy in various malignancies,
including nonsmall cell lung cancer, the benefits are less in small cell lung cancer …

Purpose Chemotherapy and concurrent thoracic radiation therapy (CCTRT) followed by
prophylactic cranial irradiation (PCI) is the standard of care for limited-stage small cell lung …

Small cell lung cancer (SCLC) is a recalcitrant cancer with an urgent need for novel
therapeutics, preclinical models, and elucidation of the molecular pathways responsible for …

Acquired radioresistance is the primary contributor to treatment failure of radiotherapy, with
ferroptosis is identified as a significant mechanism underlying cell death during …

Abstract Objectives Assess Once daily (OD) chemoradiation effectiveness for LS-SCLC
compared with twice daily (BID) chemoradiation. Methods and materials Following the …

Introduction Oncology treatments are constantly and rapidly evolving. We aimed at
highlighting the latest radiation therapy practice changing trials and emerging concepts …